Welcome to our dedicated page for KAIROS PHARMA SEC filings (Ticker: KAPA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kairos Pharma SEC filings document regulatory disclosures for a clinical-stage oncology company, including Form 8-K reports on clinical updates for ENV-105 in metastatic castration-resistant prostate cancer and non-small cell lung cancer. The filings also record material agreements tied to oncology asset rights, including license novations involving Cedars-Sinai patents and TRC105/CD105 technology.
Other filings describe proposed oncology asset transactions, executive and director equity compensation under the 2023 Equity Incentive Plan, cash bonus approvals, furnished press releases, and exhibit materials. These records outline governance actions, capital-stock award mechanics, intellectual-property and license arrangements, and event disclosures relevant to Kairos Pharma's development-stage business.
Kairos Pharma, Ltd. is asking stockholders at its June 29, 2026 virtual annual meeting to elect four directors, ratify Weinberg & Company, P.A. as auditor, and approve several governance items. Proposals include authority for a reverse stock split at a ratio between 1:3 and 1:250 and an advisory vote on executive pay.
The company also seeks approval to add 5,000,000 shares to its 2023 Equity Incentive Plan and adopt an evergreen provision for an automatic 5% annual share increase for ten years. Stockholders of record on May 15, 2026, when 21,411,198 common shares were outstanding, may vote online, by phone, mail, or during the live webcast.
Kairos Pharma, Ltd. furnished an investor presentation in connection with its appearance at the 2026 LD Micro Invitational XVI in Los Angeles. The presentation, available on the company’s website, is intended to update investors on its clinical program and partnering activities.
The materials are furnished, not filed, under Item 8.01 of the Exchange Act and attached as Exhibit 99.1, meaning they are not subject to Section 18 liability or automatically incorporated into other securities law filings.
Kairos Pharma, Ltd. reports Q1 2026 results with a net loss of $1,654 thousand, wider than $1,262 thousand a year earlier, and no revenue. Operating expenses rose to $1,690 thousand, driven by higher research and development and public-company costs.
Cash and cash equivalents were $3,675 thousand at March 31, 2026, down from $4,491 thousand at year-end 2025. The company raised gross proceeds of $385 thousand (net $367 thousand) via an At the Market equity program and has an Equity Line of Credit and a $75,000 thousand shelf registration available.
The filing states that recurring losses, cash used in operations of $1,036 thousand in the quarter, and limited cash raise substantial doubt about Kairos’s ability to continue as a going concern. The company is committing to additional manufacturing and development agreements for its ENV-105 program and has signed a binding term sheet to acquire CL-273 in exchange for equity and future milestones, increasing its need for external financing.
Kairos Pharma, Ltd. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 29, 2026. Stockholders of record as of May 15, 2026 may vote; there were 21,411,198 shares outstanding on the Record Date. The Board asks shareholders to vote on four routine governance items plus two material proposals: (1) election of four directors and (2) ratification of auditors; (3) approval of a reverse stock split authorizing the Board to combine shares at a ratio between 1:3 and 1:250; and (4) advisory approval of executive compensation. The Board also seeks approval to increase the 2023 Equity Incentive Plan by 5,000,000 shares and to add an evergreen provision granting an automatic 5% annual increase for ten years. The proxy materials and the annual report are available at kairospharma.com and via proxyvote.com.
Kairos Pharma, Ltd. is registering 6,425,000 shares of common stock for resale pursuant to a prospectus supplement dated April 1, 2026. The registration covers 2,500,000 shares underlying pre-funded warrants (exercise price $0.001), 3,750,000 shares underlying common warrants (exercise price $1.40), and 175,000 shares underlying placement-agent warrants (exercise price $1.40).
This supplement attaches the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed March 31, 2026) and updates the Prior Prospectus dated February 4, 2025. Shares underlying the warrants were issued in a private placement that closed January 16, 2025. Shares outstanding were 21,411,198 as of March 31, 2026.
Kairos Pharma, Ltd. files a prospectus supplement to update its Form S-1 registration covering up to 16,680,100 shares of common stock, reflecting (i) resale of up to $15,000,000 (approximately 15,625,000) shares issuable under an equity line of credit with Helena Global Investment Opportunities I Ltd. and (ii) 1,055,100 shares held by Helena.
The supplement attaches the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and incorporates the 10-K disclosures by reference; the prospectus remains qualified by the previously filed Prospectus dated April 25, 2025.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company developing seven oncology candidates aimed at overcoming drug resistance and immune suppression in cancers such as prostate, lung, breast cancer and glioblastoma. Its portfolio includes five Kairos-developed immunotherapies (KROS 101, 102, 201, 301 and 401) and two Enviro-originated biologics (ENV 105 and ENV 205).
ENV 105 is in a randomized Phase 2 prostate cancer trial with apalutamide and a Phase 1 trial in EGFR-mutant non-small cell lung cancer, while KROS 201 targets glioblastoma through activated T cells. ENV 205 is being advanced for chemotherapy resistance and cachexia. The company relies on extensive IP licensed from Cedars-Sinai and Tracon.
Kairos highlights recent capital raises, including a 2024 IPO, a 2025 PIPE with pre-funded and common warrants, a $30 million equity line, and a 2026 at-the-market program, but also discloses ongoing losses, substantial funding needs, and significant development, regulatory and financing risks.
Kairos Pharma, Ltd. entered into a binding term sheet to acquire 100% of the worldwide rights to CL-273, an investigational, AI-designed pan-EGFR inhibitor for EGFR-mutant non-small cell lung cancer, from Celyn Therapeutics, Inc.
As consideration, Kairos plans to issue shares so that Celyn holds 16.5% of the company on a fully diluted basis at closing, pay a $15 million milestone upon FDA NDA/BLA submission in cash and shares, and grant a 2% royalty on U.S. net revenues for the life of the applicable intellectual property. Closing is expected to be subject to shareholder approvals, absence of a material adverse effect, and any required NYSE American approval. Management highlights CL-273 as a potentially best-in-class EGFR inhibitor in an estimated $16.2 billion EGFR-mutated lung cancer market.
Kairos Pharma, Ltd. reported that it signed a letter of intent and term sheet with privately held Celyn Therapeutics to acquire worldwide rights to two oncology assets targeting non-small cell lung cancer. The drugs are CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.
The company highlights a large commercial opportunity: kinase inhibitors for cancer were valued at $60.7 billion in 2025, with EGFR inhibitors representing 32.5% and EGFR-mutated lung cancer treatment estimated at $16.2 billion in 2026. CL-741 targets a c-MET inhibitor market valued at more than $2 billion and projected to exceed $10 billion by 2030. Kairos believes combining EGFR and MET inhibition could address resistance in EGFR-mutant NSCLC and complement its existing antibody program ENV-105.